Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

35.94USD
20 Sep 2017
Change (% chg)

$0.49 (+1.37%)
Prev Close
$35.45
Open
$35.93
Day's High
$36.21
Day's Low
$35.81
Volume
18,212,908
Avg. Vol
18,881,880
52-wk High
$36.21
52-wk Low
$29.83

Select another date:
Photo

Pfizer files suit against J&J over Remicade contracts

Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson , saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

UPDATE 3-Pfizer files suit against J&J over Remicade contracts

Sept 20 Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Pfizer sues Johnson & Johnson over Remicade biosimilar

Sept 20 Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying that the drugmaker's anticompetitive contracts with health insurers prevented biosimilar competition to its blockbuster rheumatoid arthritis drug, Remicade.

BRIEF-‍Pfizer files lawsuit against Johnson & Johnson​

* ‍Pfizer says filed suit in U.S. District Court for Eastern District of Pennsylvania against Johnson & Johnson​

BRIEF-Pfizer announces outcome of FDA advisory committee meeting for Sutent

* Pfizer announces outcome of FDA advisory committee meeting for Sutent in patients at high risk of recurrent renal cell carcinoma after surgery

Pfizer, Astellas prostate cancer drug promising in late-stage trial

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.

UPDATE 3-Pfizer, Astellas prostate cancer drug promising in late-stage trial

* Pfizer's shares up 1.8 pct (Adds analysts' comments, details on drug's potential market; updates shares)

CORRECTED-UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial

Sept 14 Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.

Pfizer, Astellas prostate cancer drug clears late-stage trial

Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial.

CORRECTED-Pfizer, Astellas prostate cancer drug clears late-stage trial

Sept 14 Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

Select another date: